International Journal of Hematology

, Volume 83, Issue 4, pp 283–288 | Cite as

New Therapeutic Approach for Myeloid Leukemia: Induction of Apoptosis via Modulation of Reactive Oxygen Species Production by Natural Compounds

Progress in Hematology


The therapeutic approach to acute myeloid leukemia is based on chemotherapy, but the side effects of the drugs used and various complications, including infections and bleedings, are sometimes fatal. Recently, imatinib mesylate has shown remarkable efficacy and less toxicity as a molecularly targeted therapy in patients with chronic myeloid leukemia. Natural products appear to be safer than the current chemotherapeutic drugs, and we have therefore sought out new potential agents from various natural compounds with the ability to induce the apoptosis of myeloid leukemic cells.

Key words

AML Reactive oxygen species Apoptosis Natural compound 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Skipper HE. Thoughts on cancer chemotherapy and combination modality therapy (1974). JAMA. 1974;230:1033–1035.CrossRefGoogle Scholar
  2. 2.
    Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72:567–572.Google Scholar
  3. 3.
    Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood. 2002;99:759–767.CrossRefGoogle Scholar
  4. 4.
    Goldman JM, Melo JV. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1084–1086.CrossRefGoogle Scholar
  5. 5.
    Kizaki M, Ueno Y, Yamazoe M, et al. Mechanisms of retinoid resistance in leukemic cells: possible role of cytochrome P450 and P-glycoprotein. Blood. 1996;87:725–733.Google Scholar
  6. 6.
    Takayama N, Kizaki M,Hida T, Kinjo K, Ikeda YA Novel mutation in the PML/RARα chimeric gene exhibits dramatically decreased ligand-binding activity and confers acquired resistance to retinoic acid in acute promyelocytic leukemia. Exp Hematol. 2001;29:864–872.CrossRefGoogle Scholar
  7. 7.
    Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876–880.CrossRefGoogle Scholar
  8. 8.
    Mann J. Natural products in cancer chemotherapy: past, present and future. Nat Rev Cancer. 2002;2:143–148.CrossRefGoogle Scholar
  9. 9.
    Zubrod CG. Origins and development of chemotherapy research at the National Cancer Institute. Cancer Treat Rep. 1984;68:9–19.Google Scholar
  10. 10.
    Fukuchi Y, Kizaki M, Kinjo K, et al. Establishment of a retinoic acid-resistant acute promyelocytic leukaemia (APL) model in human granulocyte-macrophage colony-stimulating factor (hGM-CSF) transgenic severe combined immunodeficiency (SCID) mice. Br J Cancer. 1998;78:878–884.CrossRefGoogle Scholar
  11. 11.
    Pisters AMW, Newman RA, Coldman B, et al. Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol. 2001;19:1830–1838.CrossRefGoogle Scholar
  12. 12.
    Yang CS, Wang ZY. Tea and cancer. J Natl Cancer Inst. 1993;85:1038–1049.CrossRefGoogle Scholar
  13. 13.
    Asano Y, Okamura S, Ogo T, Eto T, Otsuka T, Niho Y Effect of (-)-epigallocatechin gallate on leukemic blast cells from patients with acute myeloblastic leukemia. Life Sci. 1997;60:135–142.CrossRefGoogle Scholar
  14. 14.
    Lea MA, Xiao Q, Sadhukhan AK, Cottle S, Wang ZY, Yang CS. Inhibitory effects of tea extracts and (-)-epigallocatechin gallate on DNA synthesis and proliferation of hepatoma and erythroleukemia cells. Cancer Lett. 1993;68:231–236.CrossRefGoogle Scholar
  15. 15.
    Valcic S,Timmermann BN, Alberts DS, et al. Inhibitory effect of six green tea catechins and caffeine on the growth of four selected human tumor cell lines. Anticancer Drugs. 1996;7:461–468.CrossRefGoogle Scholar
  16. 16.
    Nakazato T, Ito K, Miyakawa Y, et al. Catechin, a green tea component, rapidly induces apoptosis of myeloid leukemic cells via modulation of reactive oxygen species production in vitro and inhibits tumor growth in vivo. Haematologica. 2005;90:317–325.Google Scholar
  17. 17.
    Kizaki M, Matsushita H, Takayama N, et al. Establishment and characterization of a novel acute promyelocytic leukemia cell line (UF-1) with retinoic acid-resistant features. Blood. 1996;88:1824–1833.Google Scholar
  18. 18.
    Kinjo K, Kizaki M, Nuto A, et al. Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice. Leukemia. 2000;14:431–438.CrossRefGoogle Scholar
  19. 19.
    Nakazato T, Ito K, Ikeda Y, Kizaki M. A green tea component, catechin, induces apoptosis of human malignant B cells via production of reactive oxygen species (ROS). Clin Cancer Res. 2005;11:6040–6049.CrossRefGoogle Scholar
  20. 20.
    Monsereenusorn Y, Kongsamut S, Pezalla PD. Capsaicin: a literature survey. Crit Rev Toxicol. 1982;10:321–339.CrossRefGoogle Scholar
  21. 21.
    Lopez-Carrillo L, Hernandez Avila M, Dubrow R. Chili pepper consumption and gastric cancer in Mexico: a case-control study. Am J Epidemiol. 1994;139:263–271.CrossRefGoogle Scholar
  22. 22.
    Surh YJ, Lee SS. Capsaicin, a double-edged sword: toxicity, metabolism, and chemopreventive potential. Life Sci. 1995;56:1845–1855.CrossRefGoogle Scholar
  23. 23.
    Park KK, Surh YJ. Effects of capsaicin on chemically-induced two-stage mouse skin carcinogenesis. Cancer Lett. 1997;114:183–184.CrossRefGoogle Scholar
  24. 24.
    Yun TK. Update from Asia:Asian studies on cancer chemoprevention. Ann N Y Acad Sci. 1999;889:157–192.CrossRefGoogle Scholar
  25. 25.
    Zhang Z, Hamilton SM, Stewart C, Strother A, Teel RW. Inhibition of liver microsomal cytochrome P450 activity and metabolism of the tobacco-specific nitrosamine NNK by capsaicin and ellagic acid. Anticancer Res. 1993;13:2341–2346.Google Scholar
  26. 26.
    Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995;80:293–299.CrossRefGoogle Scholar
  27. 27.
    Toth B, Rogan E,Walker B. Tumorigenicity and mutagenicity studies with capsaicin of hot peppers. Anticancer Res. 1984;4:117–119.Google Scholar
  28. 28.
    Agrawal RC, Bhide SV. Biological studies on carcinogenicity of chillies in Balb/c mice. Indian J Med Res. 1987;86:391–396.Google Scholar
  29. 29.
    Surh YJ, Lee BC, Park KK, Mayne ST, Liem A, Miller JA. Chemo-protective effects of capsaicin and diallyl sulfide against mutagenesis or tumorigenesis by vinyl carbamate and N-nitrosodimethy-lamine. Carcinogenesis. 1995;16:2467–2471.CrossRefGoogle Scholar
  30. 30.
    Modly CE,Das M, Don PSC, Marcelo CL,Mukhtar H, Bickers DR. Capsaicin as an in vitro inhibitor of benzo(a)pyrene metabolism and its DNA binding in human and murine keratinocytes. Drug Metab Dispos. 1986;14:413–416.Google Scholar
  31. 31.
    Teel RW. Effects of capsaicin on rat liver S9-mediated metabolism and DNA binding of aflatoxin. Nutr Cancer. 1991;15:27–32.CrossRefGoogle Scholar
  32. 32.
    Richeux F, Cascante M, Ennamany R, Saboureau D, Creppy EE. Cytotoxicity and genotoxicity of capsaicin in human neuroblastoma cells SHSY-5Y. Arch Toxicol. 1999;73:403–409.CrossRefGoogle Scholar
  33. 33.
    Lee YS, Nam DH, Kim JA. Induction of apoptosis by capsaicin in A172 human glioblastoma cells. Cancer Lett. 2000;161:121–130.CrossRefGoogle Scholar
  34. 34.
    Jung MY, Kang HJ, Moon A. Caspase-induced apoptosis in SK-Hep-1 hepatocarcinoma cells involves Bcl-2 downregulation and caspase-3 activation. Cancer Lett. 2001;165:139–145.CrossRefGoogle Scholar
  35. 35.
    Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev. 1996;10:1054–1072.CrossRefGoogle Scholar
  36. 36.
    Shieh SY, Taya Y, Prives C. DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser 20, requires tetramerization. EMBO J. 1999;18:1815–1823.CrossRefGoogle Scholar
  37. 37.
    Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage-induced phos-phorylation of p53 alleviates inhibition by MDM2. Cell. 1997;91:325–334.CrossRefGoogle Scholar
  38. 38.
    Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992;69:1237–1245.CrossRefGoogle Scholar
  39. 39.
    Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323–331.CrossRefGoogle Scholar
  40. 40.
    Jimenez GS, Khan SH, Stommel JM, Wahl GM. p53 regulation by post-translational modification and nuclear retention in response to diverse stresses. Oncogene. 1999;18:7656–7665.CrossRefGoogle Scholar
  41. 41.
    Canman CE, Lim DS, Cimprich KA, et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science. 1998;281:1677–1679.CrossRefGoogle Scholar
  42. 42.
    Nakagawa K, Taya Y, Tamai K, Yamaizumi M. Requirement of ATM in phosphorylation of the human p53 protein at serine 15 following DNA double-strand breaks. Mol Cell Biol. 1999;19:2828–2834.CrossRefGoogle Scholar
  43. 43.
    Migliaccio E, Giorgio M, Mele S, et al. The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature. 1999;402:309–313.CrossRefGoogle Scholar
  44. 44.
    Li PF, Dietz R, von Harsdorf R. p53 regulates mitochondrial membrane potential through reactive oxygen species and induces cytochrome c-independent apoptosis blocked by Bcl-2. EMBO J. 1999;18:6027–6036.CrossRefGoogle Scholar
  45. 45.
    Xie S, Wang Q, Wu H, et al. Reactive oxygen species-induced phosphorylation of p53 on serine 20 is mediated in part by polo-like kinase-3. J Biol Chem. 2001;276:36194–36199.CrossRefGoogle Scholar
  46. 46.
    Banin S, Moyal L, Shieh S, et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science. 1998;281:1674–1677.CrossRefGoogle Scholar
  47. 47.
    Tibbetts RS, Brumbaugh KM, Williams JM,et al. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev. 1999;13:152–157.CrossRefGoogle Scholar
  48. 48.
    Ito K, Nakazato T, Yamato K, et al. Induction of apoptosis in leukemic cells by homovanillic acid derivative, capsaicin, through oxidative stress: implication of phosphorylation of p53 at Ser-15 residue by reactive oxygen species. Cancer Res. 2004;64:1071–1078.CrossRefGoogle Scholar
  49. 49.
    Kondo A, Ohigashi H, Murakami A, Jiwajinda S, Koshimizu K. A potent inhibitor of tumor promoter-induced Epstein-Barr virus activation, 1′-acetoxychavichol acetate from Languas galanga, a traditional Thai condiment. Biosci Biotechnol Biochem. 1993;57:1344–1345.CrossRefGoogle Scholar
  50. 50.
    Ohnishi M,Tanaka T, Makita H, et al. Chemopreventive effect of a xanthine oxidase inhibitor, 1′-acetoxychavicol acetate, on rat oral carcinogenesis. Jpn J Cancer Res. 1996;87:349–356.CrossRefGoogle Scholar
  51. 51.
    Moffatt J, Hashimoto M, Kojima A, et al. Apoptosis induced by 1′-acetoxychavicol acetate in Ehrlich ascites tumor cells is associated with modulation of polyamine metabolism and caspase-3 activation. Carcinogenesis. 2000;21:2151–2157.CrossRefGoogle Scholar
  52. 52.
    Nakamura A, Murakami A, Ohto K,Torikai T,Tanaka T, Ohigashi H. Suppression of tumor promoter-induced oxidative stress and inflammatory responses in mouse skin by a superoxide generation inhibitor 1′-acetoxychavicol acetate. Cancer Res. 1998;58:4832–4839.Google Scholar
  53. 53.
    Murakami A, Ohura S, Nakamura Y, Koshimizu K, Ohigashi H. 1′-acetoxychavicol acetate, a superoxide anion generation inhibitor, potently inhibits tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in ICR mouse skin. Oncology. 1996;53:386–391.CrossRefGoogle Scholar
  54. 54.
    Tanaka T, Makita H, Kawamori T, et al. A xanthine oxidase inhibitor 1′-acetoxychavicol acetate inhibits azoxymethane-induced colonic aberrant crypt foci in rats. Carcinogenesis. 1997;18:1113–1118.CrossRefGoogle Scholar
  55. 55.
    Tanaka T, Kawabata K, Kakumoto M, et al. Chemoprevention of azoxymethane-induced rat colon carcinogenesis by a xanthine oxidase inhibitor, 1′-acetoxychavicol acetate. Jpn J Cancer Res. 1997;88:821–830.CrossRefGoogle Scholar
  56. 56.
    Pence CB, Reiners JJ {jrJr.} Murine epidermal xanthine oxidase activity: correlation with degree of hyperplasia induced by tumor promoters. Cancer Res. 1987;47:6388–6392.Google Scholar
  57. 57.
    Ito K, Nakazato T, Murakami A, et al. Induction of apoptosis in human myeloid leukemic cells by 1′-acetoxychavicol acetate through a mitochondrial- and Fas-mediated dual mechanism. Clin Cancer Res. 2004;10:2120–2130.CrossRefGoogle Scholar
  58. 58.
    Ito K, Nakazato T, Xian MJ, et al. 1′-acetoxychavicol acetate is a novel nuclear factor κB inhibitor with significant activity against multiple myeloma in vitro and in vivo. Cancer Res. 2005;65:4417–4424.CrossRefGoogle Scholar
  59. 59.
    Muto A, Kizaki M, Kawamura C, et al. A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF. Leukemia. 2001;15:1176–1184.CrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2006

Authors and Affiliations

  1. 1.Division of HematologyKeio University School of MedicineTokyoJapan

Personalised recommendations